M Ashat1, A Lewis2, H Liaquat3, A Stocker3, L McElmurray3, V Vedanarayanan4, K Soota1, T Howell5, A Kedar6, J Obert3, T L Abell7. 1. Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Iowa, Iowa City, IA, USA. 2. Department of Internal Medicine, University of Louisville, Louisville, KY, USA. 3. Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Louisville, Louisville, KY, USA. 4. Division of Neuromuscular Medicine, University of Mississippi, Oxford, MS, USA. 5. GI Motility Clinic, Jewish Hospital, Louisville, KY, USA. 6. Division of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. 7. Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, Jewish Hospital GI Motility Clinic, University of Louisville, Louisville, KY, USA.
Abstract
BACKGROUND: Gastroparesis is a complex clinical entity; many aspects of which remain unknown. Although most patients have idiopathic, diabetic, or postsurgical gastroparesis, many are thought to have measurable neuromuscular abnormalities. Immunotherapy has recently been utilized to treat suspected autoimmune gastrointestinal dysmotility. METHODS: Fourteen patients with symptoms of gastroparesis (Gp) who were refractory to drug/device were selected from 443 Gp patients from 2013 to 2015 who were treated at the University of Louisville motility center. All patients underwent a structural and psychiatric evaluation along with detailed psychological and behavioral examination to rule out eating disorders. We performed detailed neuromuscular evaluation and all 14 patients received at least 12 weeks of intravenous immunoglobulin (400 mg/kg infusion weekly). Response was defined subjectively (symptomatic improvement) using standardized IDIOM score system. KEY RESULTS: All 14 patients had serological evidence and/or tissue evidence of immunological abnormality. Post-IVIG therapy, there was a significant improvement in symptoms scores for nausea, vomiting, early satiety, and abdominal pain. CONCLUSIONS AND INFERENCES: Although limited by the absence of placebo group, the data illustrate the role of autoimmunity and neuromuscular evaluation in patients with gastroparesis and support the utility of a diagnostic trial of immunotherapy in an effort to improve therapeutic outcomes for such patients.
BACKGROUND:Gastroparesis is a complex clinical entity; many aspects of which remain unknown. Although most patients have idiopathic, diabetic, or postsurgical gastroparesis, many are thought to have measurable neuromuscular abnormalities. Immunotherapy has recently been utilized to treat suspected autoimmune gastrointestinal dysmotility. METHODS: Fourteen patients with symptoms of gastroparesis (Gp) who were refractory to drug/device were selected from 443 Gp patients from 2013 to 2015 who were treated at the University of Louisville motility center. All patients underwent a structural and psychiatric evaluation along with detailed psychological and behavioral examination to rule out eating disorders. We performed detailed neuromuscular evaluation and all 14 patients received at least 12 weeks of intravenous immunoglobulin (400 mg/kg infusion weekly). Response was defined subjectively (symptomatic improvement) using standardized IDIOM score system. KEY RESULTS: All 14 patients had serological evidence and/or tissue evidence of immunological abnormality. Post-IVIG therapy, there was a significant improvement in symptoms scores for nausea, vomiting, early satiety, and abdominal pain. CONCLUSIONS AND INFERENCES: Although limited by the absence of placebo group, the data illustrate the role of autoimmunity and neuromuscular evaluation in patients with gastroparesis and support the utility of a diagnostic trial of immunotherapy in an effort to improve therapeutic outcomes for such patients.
Authors: Michael Camilleri; Braden Kuo; Linda Nguyen; Vida M Vaughn; Jessica Petrey; Katarina Greer; Rena Yadlapati; Thomas L Abell Journal: Am J Gastroenterol Date: 2022-06-03 Impact factor: 12.045
Authors: Henry P Parkman; Mark L Van Natta; Ashima Makol; Madhusudan Grover; Richard W McCallum; Zubair Malik; Kenneth L Koch; Irene Sarosiek; Braden Kuo; Robert J Shulman; Gianrico Farrugia; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Thomas L Abell Journal: Neurogastroenterol Motil Date: 2021-10-01 Impact factor: 3.960
Authors: Matthew Heckroth; Robert T Luckett; Chris Moser; Dipendra Parajuli; Thomas L Abell Journal: J Clin Gastroenterol Date: 2021-04-01 Impact factor: 3.174
Authors: John Michael S Sanchez; J Scott McNally; Melissa M Cortez; James Hemp; Laura A Pace; Stacey L Clardy Journal: Front Neurol Date: 2020-07-31 Impact factor: 4.003